Hennion & Walsh Asset Management Inc. Has $4.89 Million Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Hennion & Walsh Asset Management Inc. reduced its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,836 shares of the company’s stock after selling 312 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.12% of Axsome Therapeutics worth $4,894,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. JPMorgan Chase & Co. boosted its position in Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company’s stock worth $19,062,000 after acquiring an additional 27,534 shares during the last quarter. PDT Partners LLC bought a new stake in shares of Axsome Therapeutics in the third quarter worth $1,052,000. Pallas Capital Advisors LLC acquired a new position in Axsome Therapeutics during the fourth quarter worth $2,237,000. Captrust Financial Advisors bought a new position in Axsome Therapeutics in the third quarter valued at $514,000. Finally, BNP Paribas Financial Markets increased its stake in Axsome Therapeutics by 71.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,733 shares of the company’s stock valued at $1,234,000 after buying an additional 5,737 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Tuesday, December 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $121.00 price target on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price objective on shares of Axsome Therapeutics in a research note on Monday. Truist Financial raised their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a research note on Monday. Finally, Royal Bank of Canada upped their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the stock an “outperform” rating in a research report on Friday, October 4th. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Axsome Therapeutics Stock Performance

Axsome Therapeutics stock opened at $93.00 on Thursday. The business has a 50 day moving average of $92.18 and a 200-day moving average of $89.28. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a 1 year low of $64.11 and a 1 year high of $105.00. The company has a market capitalization of $4.51 billion, a P/E ratio of -14.24 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter last year, the firm earned ($1.32) earnings per share. On average, equities research analysts predict that Axsome Therapeutics, Inc. will post -4.61 earnings per share for the current year.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.